Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 29Neoplasm Metastasis 25Neoplasms 24Esophageal Neoplasms 24Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Prostatic Neoplasms 9Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Endometrial Neoplasms 8

Interventions

fludarabine 5Cyclophosphamide 5aldesleukin 4Radiotherapy 3fludarabine phosphate 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Radiation 2Papillomavirus Vaccines 2Nivolumab 2Adoptive Transfer 2trastuzumab deruxtecan 1tipifarnib 1rocakinogene sifuplasmid 1durvalumab 1bintrafusp alfa protein, human 1Watchful Waiting 1VGX-3100 1Surveys and Questionnaires 1Specimen Handling 1Ritonavir 1Quality of Life 1Psychiatric Rehabilitation 1Patient Reported Outcome Measures 1Octreotide 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Nivolumab × Gastrointestinal × Clear all
NCT06638931 2026-04-15

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
28 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡